FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801

Molecular Pathways: Dysregulated Glutamatergic Signaling Pathways in Cancer

(2012) T. D. Prickett et al.   CLINICAL CANCER RESEARCH

Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling

(2011) Alexander Herner et al.   INTERNATIONAL JOURNAL OF CANCER

Guest Editorial

(2011) Steve Siegel et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

(2010) Giles E. Hardingham et al.   NATURE REVIEWS NEUROSCIENCE

Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2

(2010) Rie Watanabe et al.   PHARMACOLOGY & THERAPEUTICS

Cancer cell lines release glutamate into the extracellular environment

(2009) Eric P. Seidlitz et al.   CLINICAL & EXPERIMENTAL METASTASIS

Expression of glutamate receptor subunits in human cancers

(2009) Andrzej Stepulak et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses

(2008) Sofia Papadia et al.   NATURE NEUROSCIENCE

The role of FoxO in the regulation of metabolism

(2008) D N Gross et al.   ONCOGENE